<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046994</url>
  </required_header>
  <id_info>
    <org_study_id>DIA-BPD</org_study_id>
    <nct_id>NCT01046994</nct_id>
  </id_info>
  <brief_title>Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion</brief_title>
  <acronym>DIA-BPD 25-30</acronym>
  <official_title>Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Chiara Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Nazionale per lo Studio e la Cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A previous prospective study of BPD effect on type 2 diabetes patients with BMI 25-35
      (DIA-CHIR) showed that T2DM is less sensitive to BPD beneficial effect in the simply
      overweight patients. A new prospective study was then planned with the aim to gain insight in
      the mechanism of action of BPD in T2DM patients in the 25-30 BMI range. Thirty patients will
      be submitted to BPD and compared with 10 nonoperated controls. Euglycemic-hyperinsulinemic
      clamp, OGTT, and mixed meal test will be performed in all subjects preoperatively, and 1
      month, 1 year, and 5 years after BPD. Complete clinical and biochemical evaluations will be
      performed at 1, 4, 8, and 12 months, and every sixth month thereafter until the end of the
      fifth year.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes control as defined by FSG and HbA1c</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes control as defined by FSG and HbA1c</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of prevalence and severity of diabetes complications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient BMI</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Biliopancreatic Diversion</condition>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biliopancreatic diversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated according to the rules of good clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biliopancreatic diversion</intervention_name>
    <description>biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve</description>
    <arm_group_label>surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidiabetics</intervention_name>
    <description>patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice</description>
    <arm_group_label>standard medical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 35-70 years

          -  diabetes duration: &gt;5 years

          -  documented poor glycemic control (HbA1c =&gt;8% despite medical treatment according to
             GCP)

          -  presence of comorbidities or complications (e.g. dyslipidemia, arterial hypertension,
             neuropathy, retinopathy, CVD, previous stroke or TIA, lower limb amputation)

          -  availability to comply with the entire follow-up

        Exclusion Criteria:

          -  general contraindications to BPD (applies also to medical controls)

          -  presence of anti-islet or anti-GAD antibodies or plasma C-peptide concentration &lt;0.5
             mcg/L

          -  blindness

          -  severe concomitant medical conditions (e.g. liver cirrhosis, renal failure, collagen
             diseases, severe endocrinopathies)

          -  heart failure

          -  recent history (less than 12 months) of myocardial infarction, stroke or TIA

          -  unstable angina

          -  pregnancy

          -  previous or concomitant malignancy

          -  severe active inflammatory, neurologic, or cardiovascular conditions

          -  geographic inaccessibility

          -  any condition which, in the opinion of the Principal Investigator, may make risky the
             participation in the study or bias the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicola Scopinaro, MD</last_name>
    <phone>+39 010 3537301</phone>
    <email>nicola.scopinaro@unige.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Scopinaro, MD</last_name>
      <phone>+39 010 3537301</phone>
      <email>nicola.scopinaro@unige.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Scopinaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>January 11, 2010</last_update_submitted>
  <last_update_submitted_qc>January 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nicola Scopinaro, Professor of Surgery</name_title>
    <organization>Azienda Ospedaliera Universitaria San Martino</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

